Recursion Pharmaceuticals, Inc. Forecasted to Post Q4 2023 Earnings of ($0.32) Per Share (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Rating) – Analysts at SVB Leerink issued their Q4 2023 earnings per share (EPS) estimates for Recursion Pharmaceuticals in a research report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar forecasts that the company will earn ($0.32) per share for the quarter. SVB Leerink has a “Market Perform” rating and a $8.00 price target on the stock. The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.38) per share.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Rating) last released its quarterly earnings data on Tuesday, November 8th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. The company had revenue of $13.16 million for the quarter, compared to the consensus estimate of $6.43 million. Recursion Pharmaceuticals had a negative return on equity of 53.04% and a negative net margin of 860.34%.

Separately, The Goldman Sachs Group raised their price objective on Recursion Pharmaceuticals from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Wednesday, November 9th.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $8.59 on Tuesday. The stock’s 50-day moving average is $8.55 and its 200-day moving average is $9.78. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -5.97 and a beta of -0.47. Recursion Pharmaceuticals has a 12 month low of $4.92 and a 12 month high of $14.18.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RXRX. CWM LLC acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Albion Financial Group UT grew its stake in Recursion Pharmaceuticals by 3,385.0% during the 3rd quarter. Albion Financial Group UT now owns 4,182 shares of the company’s stock valued at $44,000 after purchasing an additional 4,062 shares in the last quarter. Baldwin Brothers LLC MA grew its stake in Recursion Pharmaceuticals by 100.0% during the 3rd quarter. Baldwin Brothers LLC MA now owns 5,502 shares of the company’s stock valued at $59,000 after purchasing an additional 2,751 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in Recursion Pharmaceuticals by 23.2% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 7,319 shares of the company’s stock valued at $77,000 after purchasing an additional 1,378 shares in the last quarter. Finally, Centaurus Financial Inc. acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at approximately $82,000. Institutional investors and hedge funds own 63.62% of the company’s stock.

Insider Activity

In other news, insider Shafique Virani sold 10,000 shares of the stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $9.16, for a total value of $91,600.00. Following the completion of the sale, the insider now owns 73,160 shares in the company, valued at $670,145.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, COO Tina Marriott Larson sold 16,000 shares of the stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of $10.72, for a total value of $171,520.00. Following the completion of the sale, the chief operating officer now owns 205,107 shares in the company, valued at $2,198,747.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Shafique Virani sold 10,000 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $9.16, for a total value of $91,600.00. Following the completion of the sale, the insider now owns 73,160 shares of the company’s stock, valued at approximately $670,145.60. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 297,727 shares of company stock worth $2,233,995 and sold 215,713 shares worth $2,038,657. Insiders own 22.25% of the company’s stock.

Recursion Pharmaceuticals Company Profile

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

Featured Stories

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.